Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
J Hematol Oncol. 2013 Aug 2;6:55. doi: 10.1186/1756-8722-6-55.
Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma, and transformed large cell lymphoma. This review summarizes the results of current preclinical and clinical studies of lenalidomide, alone or in combination with the monoclonal antibody rituximab, as a therapeutic option for these three lymphoma types. This review will serve as a tool guiding future clinical investigations to improve survival rates for these three lymphomas.
来那度胺是一种免疫调节剂，已被批准用于多发性骨髓瘤。来那度胺对滤泡性淋巴瘤、弥漫性大 B 细胞淋巴瘤和转化大细胞淋巴瘤患者也同样有效，且耐受性良好。本综述总结了来那度胺单独或与单克隆抗体利妥昔单抗联合用于这三种淋巴瘤类型的治疗选择的当前临床前和临床研究结果。本综述将作为指导未来临床研究以提高这三种淋巴瘤生存率的工具。
